Mitsutoshi Nakamura
Overview
Explore the profile of Mitsutoshi Nakamura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
129
Citations
1584
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakazawa T, Morimoto T, Maeoka R, Yamada K, Matsuda R, Nakamura M, et al.
Int J Mol Sci
. 2024 Jun;
25(11).
PMID: 38892084
Enhancing immune cell functions in tumors remains a major challenge in cancer immunotherapy. Natural killer cells (NK) are major innate effector cells with broad cytotoxicity against tumors. Accordingly, NK cells...
2.
Nakamura M, Parkhurst S
Genetics
. 2024 Jun;
227(4).
PMID: 38874345
To survive daily damage, the formation of actomyosin ring at the wound edge is required to rapidly close cell wounds. Calcium influx is one of the start signals for these...
3.
Stjepic V, Nakamura M, Hui J, Parkhurst S
Cell Rep
. 2024 May;
43(5):114215.
PMID: 38728140
Cells have robust wound repair systems to prevent further damage or infection and to quickly restore cell cortex integrity when exposed to mechanical and chemical stress. Actomyosin ring formation and...
4.
Morimoto T, Nakazawa T, Maeoka R, Matsuda R, Nakamura M, Nishimura F, et al.
Regen Ther
. 2024 Feb;
25:367-376.
PMID: 38405180
Introduction: Innate immune cells are important in tumor immunotherapy. Natural killer cells (NKCs) are also categorized as innate immune cells and can control tumor growth and metastatic spread. Glioblastoma (GBM)...
5.
Morimoto T, Nakazawa T, Matsuda R, Maeoka R, Nishimura F, Nakamura M, et al.
Int J Mol Sci
. 2024 Feb;
25(4).
PMID: 38397112
Despite standard multimodality treatment, containing maximum safety resection, temozolomide, radiotherapy, and a tumor-treating field, patients with glioblastoma (GBM) present with a dismal prognosis. Natural killer cell (NKC)-based immunotherapy would play...
6.
Nakamura M, Parkhurst S
bioRxiv
. 2023 Dec;
PMID: 38105960
To survive daily damage, the formation of actomyosin ring at the wound periphery is required to rapidly close cell wounds. Calcium influx is one of the start signals for these...
7.
Sule K, Nakamura M, Parkhurst S
Bioessays
. 2023 Dec;
46(2):e2300182.
PMID: 38044581
Transport of macromolecules from the nucleus to the cytoplasm is essential for nearly all cellular and developmental events, and when mis-regulated, is associated with diseases, tumor formation/growth, and cancer progression....
8.
Stjepic V, Nakamura M, Hui J, Parkhurst S
bioRxiv
. 2023 Nov;
PMID: 38014090
Cells have robust wound repair systems to prevent further damage or infection and to quickly restore cell cortex integrity when exposed to mechanical and chemical stress. Actomyosin ring formation and...
9.
Maeoka R, Nakazawa T, Matsuda R, Morimoto T, Shida Y, Yamada S, et al.
Int J Mol Sci
. 2023 Sep;
24(18).
PMID: 37762486
Glioblastoma (GBM) is the leading malignant intracranial tumor, where prognosis for which has remained extremely poor for two decades. Immunotherapy has recently drawn attention as a cancer treatment, including for...
10.
Nakazawa T, Morimoto T, Maeoka R, Matsuda R, Nakamura M, Nishimura F, et al.
J Exp Clin Cancer Res
. 2023 Aug;
42(1):205.
PMID: 37563692
Background: Glioblastoma (GBM) is the most common malignant brain tumor and has "immunologically cold" features. Changing GBM to an "immunologically hot" tumor requires a strong trigger that induces initial immune...